Drug intelligence / Profile preview

AVT65

Development stage: Preclinical
Lead developer: Alvotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

AVT65 is a biosimilar candidate developed by Alvotech. It is a fully human anti-CD20 monoclonal antibody, designed to be a biosimilar to Kesimpta (ofatumumab). It targets the CD20 protein on B-cells, leading to their depletion through mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). It is being developed for the treatment of relapsing forms of multiple sclerosis.

Targets

IL12B (Interleukin-12/23 p40 subunit)

Beyond the preview

Go deeper on AVT65.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVT65.

Explore the full profile